Table 1.

Demographic and clinical data of study patient population.

	All patients (n=300)		Asymptomatic Swallowing (n=266)		Chronic-RAD (n=34)
T-category	n.	Percent	n.	Percent	n.	Percent
1	53	17.67%	51	19.17%	2	5.88%
2	139	46.33%	128	48.12%	11	32.35%
3	68	22.67%	60	22.56%	8	23.53%
4	40	13.33%	27	10.15%	13	38.24%
N-category
0	16	5.33%	14	5.26%	2	5.88%
1	12	4.00%	12	4.51%	0	0.00%
2a	21	7.00%	21	7.89%	0	0.00%
2b	167	55.67%	150	56.39%	17	50.00%
2c	71	23.67%	57	21.43%	14	41.18%
3	13	4.33%	12	4.51%	1	2.94%
Site
Base of tongue	164	54.67%	144	54.14%	20	58.82%
Tonsil	131	43.67%	118	44.36%	15	44.12%
Other	5	1.67%	4	1.50%	1	2.94%
Smoking status
Never	55	18.33%	46	17.29%	9	26.47%
<10 pack-years	109	36.33%	99	37.22%	10	29.41%
>10 pack-years	136	45.33%	121	45.49%	15	44.12%
Sex
Male	272	90.67%	238	89.47%	34	100.00%
Female	28	9.33%	28	10.53%	0	0.00%
Ethnicity
White	283	94.33%	251	94.36%	32	94.12%
Black	7	2.33%	6	2.26%	1	2.94%
Hispanic	9	3.00%	8	3.01%	1	2.94%
Asian/Pacific Islander	1	0.33%	1	0.38%	0	0.00%
Chemotherapy
Cisplatin	195	65.00%	99	37.22%	6	17.65%
Cetuximab	105	35.00%	167	62.78%	28	82.35%
IMRT technique
Split-field	284	94.6%	253	95%	31	91%
Whole-field	16	5.4%	13	5%	3	9%
IMRT fractionation
Once-daily	262	87%	233	87.5%	29	85%
Accelerated	38	13%	33	12.5%	5	15%
	Mean±SD	Median (Range)	Mean±SD	Median (Range)	Mean±SD	Median (Range)
Age (years)	56±9	56 (28–81)	56±8	55 (36–81)	59±10	59 (28–81)
RT dose (Gy)	69±2	70 (64–75)	68±2	70 (64–75)	70±1	70 (66–72)
RT fractions delivered	33±2	33 (29–35)	33±2	33 (29–35)	33±2	33 (30–35)